Safety [clinicaltrials_resource:76cf022fce702c91eabb4f1257dc0425]

Safety [clinicaltrials_resource:76cf022fce702c91eabb4f1257dc0425]

Voluven will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:76cf022fce702c91eabb4f1257dc0425
Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization [clinicaltrials:NCT00317512]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Safety [clinicaltrials_resource:76cf022fce702c91eabb4f1257dc0425]

Voluven will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:76cf022fce702c91eabb4f1257dc0425
Bio2RDF identifier
76cf022fce702c91eabb4f1257dc0425
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:76cf022fce702c91eabb4f1257dc0425
measure [clinicaltrials_vocabulary:measure]
description
Voluven will be administered a ...... at 7.7 ml/min over 15 minutes
identifier
clinicaltrials_resource:76cf022fce702c91eabb4f1257dc0425
title
Safety
@en
inDataset
type
label
Safety [clinicaltrials_resource:76cf022fce702c91eabb4f1257dc0425]
@en